Cetuximab for head and neck and colorectal cancer - horizon scanning review

NHSC
Record ID 32002000534
English
Authors' objectives:

To summarise the available evidence on cetuximab for head and neck and colorectal cancer.

Authors' recommendations: - Clinical impact: Although the number of patients with advanced head and neck cancer is relatively small, their prognosis is poor and their treatment options are limited and most have severe adverse effects on quality of life. The number of people with advanced colorectal cancer is much more significant, but there are more alternative therapies. - Service impact: There will be little additional impact on current services as cetuximab is currently given in combination with radio- or chemotherapy. - Additional factors: Patients with refractory cancer will welcome any therapy that could prolong survival and especially one with relatively few adverse effects. - Financial and overall NHS impact: It is impossible to predict the overall impact of cetuximab on the NHS or costs at this stage of development, but any costs associated with its use will be in addition to current drug costs and could be substantial.
Authors' methods: Overview
Details
Project Status: Completed
Year Published: 2002
URL for published report: http://www.hsric.nihr.ac.uk/search
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Antibodies, Monoclonal
  • Colorectal Neoplasms
  • Head and Neck Neoplasms
Contact
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name: c.packer@bham.ac.uk
Contact Email: c.packer@bham.ac.uk
Copyright: National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.